Applications

1792 – Immunohistochemistry testing for fibroblast growth factor receptor 2b (FGFR2b) expression in patients with unresectable locally advanced or metastatic gastric or gastro-oesophageal cancer, to determine eligibility for PBS subsidised bemarituzumab treatment

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type New application
  • Pre-PASC consultation Open
  • Pre-MSAC consultation -
  • Outcome Pending

Application details

Applicant

Amgen Australia Pty Limited

Reason for application

New Medicare Benefits Schedule item for codependent application (MSAC and Pharmaceutical Benefits Advisory Committee).

Service or technology in this application

A test to measure the expression of fibroblast growth factor receptor 2b (FGFR2b) in patients with unresectable locally advanced or metastatic gastric or gastro-oesophageal cancer. The results of the test will be used to determine eligibility for a potential new PBS subsidised treatment, bemarituzumab.

Type: Investigative technology

Medical condition this application addresses

The proposed treatment is intended for patients with unresectable locally advanced or metastatic gastric or gastro-oesophageal cancer. Gastric or gastro-oesophageal junction cancer occurs in the epithelial lining of the stomach and the gastro-oesophageal junction between the stomach and the oesophagus. 

Application documents

Application summary

PICO set

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Consultation survey and deadlines

The following consultation deadlines apply:

  • Pre-PASC consultation deadline: 14 March 2025
  • Pre-MSAC consultation deadline: -

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

Meetings to consider this application

This application will be considered at the following meetings:

  • PASC meeting: 16 to 17 April 2025
  • ESC meeting: - 
  • MSAC meeting: -

Find out more about our meetings.

Outcome details

The outcome of this application is pending.

More information

Find out more about: